The potential of biomarkers in psychiatry: focus on proteomics

Journal of Neural Transmission

Volumn 122, Issue , 2015, Pages 9-18

  Sokolowska, Izabela ^a   Ngounou Wetie, Armand G ^a   Wormwood, Kelly ^a   Thome, Johannes ^b   Darie, Costel C ^a   Woods, Alisa G ^a  

^a CLARKSON UNIVERSITY   (United States)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Biomarkers; Mass spectrometry; Proteomics; Psychiatry

Indexed keywords

APOLIPOPROTEIN; BIOLOGICAL MARKER; COMPLEMENT; DOPAMINE; DOPAMINE TRANSPORTER; NEUROPEPTIDE Y; NORADRENALIN; PRASTERONE; SEROTONIN;

ATTENTION DEFICIT DISORDER; AUTISM; DEPRESSION; DIAGNOSTIC TEST; HUMAN; MAJOR DEPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; PSYCHIATRIC DIAGNOSIS; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; SCREENING TEST; MENTAL DISEASE; METABOLISM;

BIOMARKERS; HUMANS; MENTAL DISORDERS; PROTEOMICS; PSYCHIATRY;

EID: 84938984909     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1134-6     Document Type: Review

References (122)

1. APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn. VA: American Psychiatric Association, Arlington
2. American Psychiatric Association (2000) Task force on DSM-IV, diagnostic and statistical manual of mental disorders: DSM-IV-TR, 4th edn. American Psychiatric Association, Washington, DC, p 943
3. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators (2012) Prevalence of autism spectrum disorders–autism and developmental disabilities monitoring Network, 14 sites, United States, 2008. MMWR surveill summ. 61(3):1–19
4. Barnett JH, Smoller JW (2009) The genetics of bipolar disorder. Neuroscience 164(1):331–343
5. Beasley CL et al (2006) Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6(11):3414–3425
6. Berger I (2011) Diagnosis of attention deficit hyperactivity disorder: much ado about something. Isr Med Assoc J 13(9):571–574
7. Blumberg SJ et al (2013) Changes in prevalence of parent-reported autism spectrum disorder in school-aged US children: 2007 to 2011–2012, national health statistics reports no 65., D.o.H.a.H. services, (ed), centers for disease control and prevention, national center for health statistics: Hyattsville, MD
8. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95
9. Brown RT et al (2001) Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 107(3):43
10. Bremner JD et al (1995) MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatr 152(7):973–981
11. Busse S et al (2012) Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis. Eur Arch Psychiatr Clin Neurosci 262(5):365–374
12. Carboni L et al (2006) Proteomic analysis of rat hippocampus after repeated psychosocial stress. Neuroscience 137(4):1237–1246
13. Caspi A et al (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631):386–389
14. Castagnola M et al (2008) Hypo-phosphorylation of salivary peptidome as a clue to the molecular pathogenesis of autism spectrum disorders. J Proteome Res 7(12):5327–5332
15. Cecconi D et al (2007) Proteomic analysis of rat cortical neurons after fluoxetine treatment. Brain Res 1135(1):41–51
16. Ceylan MF et al (2012) Changes in oxidative stress and cellular immunity serum markers in attention-deficit/hyperactivity disorder. Psychiatr Clin Neurosci 66(3):220–226
17. Claassen CA et al (2007) Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. J Affect Disord 97(1–3):77–84
18. Corbett BA et al (2007) A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatr 12(3):292–306
19. Cook IA (2008) Biomarkers in psychiatry: potentials, pitfalls, and pragmatics. Primary Psychiatr 15(3):54–59
20. Darie CC et al (2004) Structural characterization of fish egg vitelline envelope proteins by mass spectrometry. Biochemistry 43(23):7459–7478
21. Darie CC et al (2005a) Isolation and structural characterization of the Ndh complex from mesophyll and bundle sheath chloroplasts of Zea mays. FEBS J 272(11):2705–2716
22. Darie CC et al (2005b) Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg. J Biol Chem 280(45):37585–37598
23. Darie, CC, Shetty V, Spellman DS, Zhang G, Xu C, Cardasis HL, Blais S, Fenyo D, Neubert, T. A (2008a) Applications of mass spectrometry in life safety, NATO science for peace and security series. In: Popescu C, Zamfir AD, Dinca N (eds.) Blue native PAGE and mass spectrometry analysis of the ephrin stimulation- dependent protein-protein interactions in NG108-EphB2 cells. Springer Düsseldorf, Germany, pp 3–22
24. Darie CC, E.S. Litscher, and P.M. Wassarman (2008b) Applications of mass spectrometry in life safety, NATO science for peace and security series. In: Popescu C, Zamfir AD, Dinca N (eds.) Structure, processing, and polymerization of rainbow trout egg vitelline envelope proteins. Springer, Düsseldorf, Germany, pp 23–36
25. Darie CC et al (2011) Identifying transient protein-protein interactions in EphB2 signaling by blue native PAGE and mass spectrometry. Proteomics 11(23):4514–4528
26. Darie C (2013) Investigation of protein-protein interactions by blue native-PAGE & mass spectrometry. Mod Chem Appl 1(3):111
27. Falkai P, Moller HJ (2012) Biomarkers and neurobiology of schizophrenia. Eur Arch Psychiatr Clin Neurosci 262(5):363–364
28. Faraone SV, Mick E (2010) Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 33(1):159–180
29. FDA warning letter (2013) Inspections, compliance, enforcement, and criminal investigations. Accessed from: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm
30. Froehlich TE, McGough JJ, Stein MA (2010) Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24(2):99–117
31. Genomind (2012). The Genecept Assay. Available from: https://www.genomind.com/products/assay. Cited 26 Sep 12
32. Gizer IR, Ficks C, Waldman ID (2009) Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126(1):51–90
33. Glessner JT, Hakonarson H (2009) Common variants in polygenic schizophrenia. Genome Biol 10(9):236
34. Gygi SP et al (1999a) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19(3):1720–1730
35. Gygi SP et al (1999b) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17(10):994–999
36. Hagerman R et al (2012) Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 54:297–335
37. Hamacher M, Meyer HE (2005) HUPO brain proteome project: aims and needs in proteomics. Expert Rev Proteomics 2(1):1–3
38. Howes OD et al (2009) Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 15(22):2550–2559
39. Ideker T et al (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292(5518):929–934
40. Jaros JA et al (2012) Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls. J Proteomics 76 Spec No.:43–55. doi:10.1016/j.jprot.2012.05.027
41. Junaid MA, Pullarkat RK (2001) Proteomic approach for the elucidation of biological defects in autism. J Autism Dev Disord 31(6):557–560
42. Junaid MA et al (2004) Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A 131(1):11–17
43. Johnston-Wilson NL et al (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The stanley neuropathology consortium. Mol Psychiatr 5(2):142–149
44. Khawaja X et al (2004) Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 75(4):451–460
45. Krishnadas R, Cavanagh J (2012) Depression: an inflammatory illness? J Neurol Neurosurg Psychiatr 83(5):495–502
46. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatr 167(11):1305–1320
47. Kubera M et al (2001) Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 21(2):199–206
48. Kubera M et al (2004) Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 4(2):185–192
49. Kvajo M, McKellar H, Gogos JA (2010) Molecules, signaling, and schizophrenia. Curr Top Behav Neurosci 4:629–656
50. Lakhan SE, Vieira K, Hamlat E (2010) Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med 3:1
51. Lakhan SE (2006) Schizophrenia proteomics: biomarkers on the path to laboratory medicine? Diagn Pathol 1:11
52. Lakhan SE, Kramer A (2009) Schizophrenia genomics and proteomics: are we any closer to biomarker discovery? Behav Brain Funct 5:2
53. Levin Y et al (2010) Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatr 15(11):1088–1100
54. Le-Niculescu H et al (2009) Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatr 14(2):156–174
55. Lesko LJ, Atkinson AJ Jr (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347–366
56. Li M, Soczynska JK, Kennedy SH (2011) Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Curr Psychiatr Rep 13(5):316–320
57. Maes M (2001) The immunoregulatory effects of antidepressants. Hum Psychopharmacol 16(1):95–103
58. Martins-de-Souza D (2010) Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? Eur Arch Psychiatr Clin Neurosci 260(7):561–562
59. Martins-De-Souza D et al (2010a) Proteome analysis of schizophrenia brain tissue. World J Biol Psychiatr 11(2):110–120
60. Martins-de-Souza D et al (2010b) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 44(16):1176–1189
61. Martins-de-Souza D et al (2010c) The role of proteomics in depression research. Eur Arch Psychiatr Clin Neurosci 260(6):499–506
62. McGough JJ (2012) Attention deficit hyperactivity disorder pharmacogenetics: the dopamine transporter and D4 receptor. Pharmacogenomics 13(4):365–368
63. Molloy CA et al (2006) Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 172(1–2):198–205
64. Moriarty M et al (2011) Development of an LC-MS/MS method for the analysis of serotonin and related compounds in urine and the identification of a potential biomarker for attention deficit hyperactivity/hyperkinetic disorder. Anal Bioanal Chem 401(8):2481–2493
65. Moriarty M et al (2012) Development of a nano-electrospray MSn method for the analysis of serotonin and related compounds in urine using a LTQ-orbitrap mass spectrometer. Talanta 90:1–11
66. Mu J et al (2007) Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model. Neurosci Lett 416(3):252–256
67. Muller TJ et al (1997) A comparison of qEEG and HMPAO-SPECT in relation to the clinical severity of Alzheimer’s disease. Eur Arch Psychiatr Clin Neurosci 247(5):259–263
68. Muller N, Myint AM, Schwarz MJ (2011) Inflammatory biomarkers and depression. Neurotox Res 19(2):308–318
69. Neale BM et al (2012) Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485(7397):242–245
70. Ng MY et al (2009) Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatr 14(8):774–785
71. Ngounou Wetie AG et al (2012) Automated mass spectrometry-based functional assay for the routine analysis of the secretome. J Lab Autom 18(1):19–29
72. Ngounou Wetie AG et al (2013a) Identification of post-translational modifications by mass spectrometry. Australian J Chem 66:734–748
73. Ngounou Wetie AG et al (2013b) Protein-protein interactions: switch from classical methods to proteomics and bioinformatics-based approaches. Cell Mol Life Sci [Epub ahead of print]
74. Ngounou Wetie AG et al (2013c) Investigation of stable and transient protein-protein interactions: past, present, and future. Proteomics 13(3–4):538–557
75. Ngounou Wetie AG et al (2013d) Automated mass spectrometry-based functional assay for the routine analysis of the secretome. J Lab Autom 18(1):19–29
76. Ngounou Wetie A.G et al (2013e) Mass spectrometry for the detection of potential psychiatric biomarkers. J Mol Psychiatr 1:8. http://www.jmolecularpsychiatry.com/content/1/1/8
77. Pallis AG et al (2011) Biomarkers of clinical benefit from anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer 105:1–8
78. Pies R (2008) Psychiatric diagnosis and the pathologist’s view of schizophrenia. Psychiatry 5(7):62–65
79. Poelmans G et al (2011) Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatr 168(4):365–377
80. Purcell SM et al (2009) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460(7256):748–752
81. Ross JS (2011) Biomarker-based selection of therapy for colorectal cancer. Biomark Med 5(3):319–332
82. Roy U et al (2012) Structural investigation of tumor differentiation factor (TDF). Biotech App Biochem 59(6):445–450
83. Saraceno B (2002) The WHO world health report 2001 on mental health. Epidemiol Psichiatr Soc 11(2):83–87
84. Scassellati C, Bonvicini C, Faraone SV, Gennarelli M (2012) Biomarkers and attention-deficit/hyperactivity disorder: a systematic review and meta-analyses. J American Aca Child Adoles Psychiatr 51(10):1003–1019
85. Schroeter ML et al (2010) Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatr Neurol 2010:780645
86. Schroeter ML, Steiner J, Mueller K (2011) Glial pathology is modified by age in mood disorders–a systematic meta-analysis of serum S100B in vivo studies. J Affect Disord 134(1–3):32–38
87. Shi M et al (2011) Salivary tau species are potential biomarkers of Alzheimer’s disease. J Alzheimers Dis 27(2):299–305
88. Singh I, Rose N (2009) Biomarkers in psychiatry. Nature 460(7252):202–207
89. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30(11):563–569
90. Sokolowska I et al (2011) Mass spectrometry for proteomics-based investigation of oxidative stress and heat shock proteins. In: Andreescu S, Hepel M (eds) Oxidative stress: diagnostics, prevention, and therapy. American Chemical Society, Washington, D.C
91. Sokolowska I et al (2012a) Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells. Proteome Sci 10(1):47
92. Sokolowska I et al (2012b) Disulfide proteomics for identification of extracellular or secreted proteins. Electrophoresis 33(16):2527–2536
93. Sokolowska I et al (2012c) Identification of a potential tumor differentiation factor receptor candidate in prostate cancer cells. FEBS J 279(14):2579–2594
94. Sokolowska I et al (2012d) Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R). Cell Mol Life Sci 70:2835–2848
95. Sokolowska I et al (2013a) Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins. Biochim Biophys Acta 1834(8):1474–1483
96. Sokolowska I et al (2013b) Applications of mass spectrometry in proteomics. Australian J Chem 66(7):721–733
97. Spahis S et al (2008) Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 79(1–2):47–53
98. Spellman DS et al (2008) Stable isotopic labeling by amino acids in cultured primary neurons: application to brain-derived neurotrophic factor-dependent phosphotyrosine-associated signaling. Mol Cell Proteomics 7(6):1067–1076
99. Stephan C et al (2005) HUPO brain proteome project pilot studies: bioinformatics at work. Proteomics 5(11):2716–2717
100. Swanson JM et al (2007) Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17(1):39–59
101. Tan MH (2009) Advancing civil rights, the next generation: the genetic information nondiscrimination act of 2008 and beyond. Health Matrix Clevel 19(1):63–119
102. Taurines R et al (2010) Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry. Eur Arch Psychiatr Clin Neurosci 260(3):249–255
103. Taurines R et al (2011) Proteomic research in psychiatry. J Psychopharmacol 25(2):151–196
104. Thome J et al (2012) Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the world federation of ADHD. World J Biol Psychiatr 13(5):379–400
105. To SE, Zepf RA, Woods AG (2005) The symptoms, neurobiology, and current pharmacological treatment of depression. J Neurosci Nurs 37(2):102–107
106. Turck CW, Iris F (2011) Proteome-based pathway modelling of psychiatric disorders. Pharmacopsychiatry 44(Suppl 1):S54–S61
107. van Os J, Kapur S (2009) Schizophrenia. Lancet 374(9690):635–645
108. Vasic N et al (2012) Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand? Eur Arch Psychiatr Clin Neurosci 262(5):375–391
109. Viswanathan S, Unlu M, Minden JS (2006) Two-dimensional difference gel electrophoresis. Nat Protoc 1(3):1351–1358
110. Whalley MG, Rugg MD, Brewin CR (2012) Autobiographical memory in depression: an fMRI study. Psychiatr Res 201(2):98–106
111. Wilkins MR et al (1996) Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13:19–50
112. Williams LM et al (2011) International study to predict optimized treatment for depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 12:4
113. Winton-Brown TT, Kapur S (2009) Neuroimaging of schizophrenia: what it reveals about the disease and what it tells us about a patient. Ann Acad Med Singapore 38(5):433
114. Woods AG et al (2011) Blue native page and mass spectrometry as an approach for the investigation of stable and transient protein-protein interactions. In: Andreescu S, Hepel M (eds) Oxidative stress: diagnostics, prevention, and therapy. American Chemical Society, Washington, D.C
115. Woods AG et al (2012a) Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 16(6):1184–1195
116. Woods AG, Sokolowska I, Darie CC (2012b) Identification of consistent alkylation of cysteine-less peptides in a proteomics experiment. Biochem Biophys Res Commun 419(2):305–308
117. Woods AG, Mahdavi E, Ryan JP (2013a) Treating clients with asperger’s syndrome and autism. Child Adolesc Psychiatr Ment Health 7(1):32
118. Woods AG et al (2013b) Mass spectrometry as a tool for studying autism spectrum disorder. J Mol Psychiatr 1:6. doi:10.1186/2049-9256-1-6
119. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva, p 362
120. Yang Y et al (2006) Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78(11):3571–3576
121. Zhu W, Smith JW, Huang CM (2010) Mass spectrometry-based label-free quantitative proteomics. J Biomed Biotechnol 2010:840518
122. Zimmerman AW et al (2005) Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 33(3):195–201